The release of IL-6 and IL-21 by polyclonally activated CD4+ T cells derived from NMO patients was demonstrated to correlate directly with neurological disability [63] and in vivo and in vitro levels of IL-6 were higher among NMO patients who experienced relapse within a 2-year follow-up [64]. The gene discussed is IL21; the disease is neuromyelitis optica.